William Blair Has Bullish Forecast for Enovis Q1 Earnings

Enovis Co. (NYSE:ENOV - Free Report) - Equities researchers at William Blair upped their Q1 2025 earnings per share (EPS) estimates for shares of Enovis in a report issued on Wednesday, February 26th. William Blair analyst B. Vazquez now anticipates that the company will post earnings of $0.75 per share for the quarter, up from their previous forecast of $0.70. The consensus estimate for Enovis' current full-year earnings is $2.79 per share. William Blair also issued estimates for Enovis' Q2 2025 earnings at $0.70 EPS, Q3 2025 earnings at $0.76 EPS, FY2025 earnings at $3.16 EPS, Q1 2026 earnings at $0.82 EPS, Q2 2026 earnings at $0.77 EPS, Q3 2026 earnings at $0.84 EPS, Q4 2026 earnings at $1.05 EPS and FY2026 earnings at $3.48 EPS.

Enovis (NYSE:ENOV - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.92 by $0.06. The business had revenue of $560.98 million for the quarter, compared to analysts' expectations of $555.14 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%.

Separately, Needham & Company LLC lowered their price objective on Enovis from $65.00 to $64.00 and set a "buy" rating on the stock in a research report on Thursday.

Enovis Stock Performance

Shares of ENOV traded down $0.82 on Friday, reaching $37.83. 1,653,938 shares of the stock traded hands, compared to its average volume of 1,013,966. The firm has a market cap of $2.15 billion, a price-to-earnings ratio of -17.27 and a beta of 1.94. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. Enovis has a 12 month low of $37.60 and a 12 month high of $63.96. The stock's 50-day moving average price is $44.72 and its 200-day moving average price is $44.28.

Institutional Trading of Enovis

Several institutional investors have recently bought and sold shares of ENOV. River Road Asset Management LLC acquired a new stake in Enovis in the 3rd quarter valued at $51,341,000. Hood River Capital Management LLC acquired a new stake in Enovis in the 4th quarter valued at $29,024,000. Paradigm Capital Management Inc. NY boosted its stake in Enovis by 2,566.0% in the 4th quarter. Paradigm Capital Management Inc. NY now owns 533,200 shares of the company's stock valued at $23,397,000 after buying an additional 513,200 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Enovis in the 4th quarter valued at $16,407,000. Finally, Royce & Associates LP boosted its stake in Enovis by 16.8% in the 3rd quarter. Royce & Associates LP now owns 2,403,685 shares of the company's stock valued at $103,479,000 after buying an additional 346,317 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company's stock.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.